Traws Pharma, Inc.

Traws Pharma, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing antiviral and oncology product candidates. Its pipeline includes TRX01 (ratutrelvir), a SARS-CoV-2 main protease inhibitor, and tivoxavir marboxil, along with other in-licensed or acquired drug programs.

−638,5 %

328,7 %

+1 134,5 %

0.72

0.72

— Traws Pharma, Inc.
%
Antiviral drug candidates70% Development-stage antiviral programs targeting viral replication and infection.
Oncology programs20% Preclinical or clinical oncology assets pursued through partnerships or internal development.
Licensing revenue10% Revenue from collaboration and license agreements tied to deferred or milestone-based recognition.

Traws Pharma does not sell commercial medicines directly today; its economic counterparties are primarily...

  • Pharmaceutical and biotechnology partnersprimary

    License or collaborate on assets for funding, development, and eventual commercialization.

  • Clinical trial ecosystemprimary

    Investigators, sites, and participants used to generate safety and efficacy data.

  • Regulatory agenciesprimary

    FDA and foreign regulators that review protocols, data, and approvals.

  • Future healthcare providers and patientsemerging

    Would buy approved antiviral or oncology therapies through the healthcare system.

Traws Pharma is headquartered in the United States and conducts its development and regulatory activities primarily...

  • •United States is the core operating and regulatory base
  • •Clinical development has included trial activity in Australia
  • •Future commercialization may extend to other territories
  • •U.S. FDA and SEC access is important to development and financing
  • •Foreign regulatory pathways matter for global partnering

The company’s strategy is to advance its antiviral and oncology pipeline through clinical development, regulatory...

01
Advance clinical programsshort-term

Clinical proof-of-concept is the main value driver for a development-stage biotech.

02
Secure funding and partnershipsshort-term

The company needs external capital and collaborators to sustain development.

03
Build commercialization optionalitymedium-term

Approved products will require a route to market, either internal or partnered.

Traws Pharma faces the classic risks of a clinical-stage biotech: uncertain trial outcomes, regulatory approval risk,...

critical

Financing and going-concern risk

The company requires substantial additional capital to fund operations and trials.

Scope
Equity, debt, ATM, and strategic financing
Materiality
high
high

Clinical development failure or delay

Pipeline value depends on successful trial design, enrollment, and efficacy/safety results.

Scope
TRX01 and tivoxavir marboxil programs
Materiality
high
high

Regulatory approval risk

Drug candidates must satisfy FDA and other regulators before commercialization.

Scope
Trial protocols, labeling, and approval timing
Materiality
high
high

Government shutdown and budget disruption

FDA, SEC, and other agencies may delay reviews and filings during shutdowns.

Scope
Regulatory submissions and capital raising
Materiality
medium
medium

Partnering and commercialization risk

The company lacks a full commercial organization and may rely on third parties.

Scope
Licensing, co-promotion, and market access
Materiality
medium
Revenue recognition and deferred revenue
Can create lumpy quarterly revenue
Fair value of warrant liability
Affects reported net income without changing cash flow
Acquired in-process research and development
Can cause large one-time operating expense charges
Accrued expenses and clinical trial estimates
Affects operating expense timing and comparability
Contingent value rights
Requires judgment in liability measurement

Terns Pharmaceuticals, Inc.

Pharmaceutical Preparations

Trevi Therapeutics, Inc.

TRVI · Pharmaceutical Preparations

Voyager Therapeutics, Inc.

VYGR · Biological Products, (No Diagnostic Substances)

Kairos Pharma, LTD.

KAPA · Pharmaceutical Preparations

Janux Therapeutics, Inc.

JANX · Pharmaceutical Preparations

MACROGENICS INC

MGNX · Pharmaceutical Preparations

: 29/04/2026